Everbright embeds TMS and SPRAVATO® service lines directly into mental health practices. We handle the infrastructure, staffing, prior authorization, and patient activation — so your team stays focused on care.
Transcranial Magnetic Stimulation is an FDA-cleared, non-invasive treatment for major depressive disorder with strong clinical evidence and high patient tolerability. TMS is covered by most major insurers for patients who haven't responded to medication.
SPRAVATO® (esketamine) is FDA-approved for treatment-resistant depression and major depressive disorder with suicidal ideation. Administered in a certified healthcare setting, it offers a rapid-acting alternative for patients who haven't responded to oral antidepressants alone.
Treatment-eligible patients are automatically identified using clinical and payor-specific criteria and engaged and educated through multiple channels.
Equipment, trained staff, templates, and clinical protocols embedded directly into your practice.
End-to-end prior authorization management with 2x industry approval rates.
Full RCM management so your team stays focused on care.
Structured clinical data across PHQ-9, GAD-7, and treatment response metrics.
We'll analyze your panel in Activate™ and show you exactly which of your patients qualify.